Targeting the TNF-alpha pathway in sarcoidosis

Expert Opin Ther Targets. 2010 Jan;14(1):21-9. doi: 10.1517/14728220903449244.

Abstract

IMPORTANCE OF THE FIELD/SIGNIFICANCE: Sarcoidosis is a granulomatous disease with various organ manifestations in which TNF-alpha has been demonstrated to play a major pathogenic role. The existing conventional therapies are not always able to minimize TNF-alpha-driven inflammation and other approaches should be used.

Areas covered in this review: TNF-alpha roles in sarcoid inflammation and granuloma formation are reviewed based on the literature published in the last two decades and the therapies able to target it specifically or non-specifically in sarcoidosis are discussed.

What the reader will gain: A better understanding of the pathogenic role of TNF-alpha in sarcoidosis and of the scientific rationale of its therapeutic blockade.

Take home message: In some subsets of sarcoidosis with more rapid progession and/or therapeutic refractoriness TNF-alpha plays a more prominent role in disease pathogenesis, and its blockade might represent an appropriate therapeutic approach.

Publication types

  • Review

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Pentoxifylline / therapeutic use
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Sarcoidosis / drug therapy*
  • Sarcoidosis / pathology
  • Signal Transduction / drug effects
  • Thalidomide / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / physiology*

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Thalidomide
  • Infliximab
  • Adalimumab
  • Etanercept
  • Pentoxifylline